COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE.

“ Oncogenic NRAS plays a critical role in melanoma initiation and maintenance; however, to date there are no effective ways to directly block the activity of mutant NRAS. ” NRAS is the second most common oncogenic driver in melanoma, mutated predominantly at codon 61 in almost 30% of all melanomas [1] . Tumors bearing NRAS mutations are highly aggressive and are associated with shorter patient survival [2] . Despite the prevalence of NRAS mutations and the severity of the resulting disease, treatment for NRAS mutant melanoma has lagged far behind BRAF-mutant tumors. Here, we summarize the status of the most promising strategies, highlighting the successes and the gaps that remain to be filled. GTP guanine-nucleotide exchange mutant form of to GAPs, leading to NRAS activation and persistent signaling that triggers and